Jardiance is the first SGLT2-inhibitor therapy to prove reduction in risk of cardiovascular death in people with type-II diabetes and established cardiovascular disease
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes
BRIDGE-1 Comprehensive care programme for Type 1 diabetes and to train 400 physicians and benefit over 1000 children
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
The collaboration provides KardiaMobile users quick access to doctors worldwide for consultations about their ECG readings
This capability programme aims to upskill 5000 nurses across the country in the next year by converting the current modules into an e-learning one
Cipla has reported consolidated financial results for the period ended September 30, 2021
It answers the most basic questions from a patient’s perspective
A total of 12 generic medicines have been included in the list
Subscribe To Our Newsletter & Stay Updated
